REDUCE Trial- Reducing Prolapse Recurrence

Sponsor
Northwestern University (Other)
Overall Status
Recruiting
CT.gov ID
NCT04880239
Collaborator
The Institute of Pelvic Medicine & Reconstructive Surgery, Allentown, Pennsylvania (Other), University of Kansas (Other)
200
1
2
32.2
6.2

Study Details

Study Description

Brief Summary

This study will examine whether surgeons should add a prophylactic posterior colpoperineorrhaphy to a mesh-augmented apical prolapse repair.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Posterior colpoperineorrhaphy
N/A

Detailed Description

The decision to perform a posterior colpoperineorrhaphy at the time of sacrocolpopexy is controversial. Based on cohort data, some surgeons advocate that sacrocolpopexy alone is effective at treating posterior vaginal wall prolapse and the addition of posterior colpoperineorrhaphy only increases the likelihood of pain with defecation and dyspareunia. Experts theorize that placement of posterior vaginal mesh down to the perineal body provides adequate posterior support and reduces genital hiatus size. Others argue that placement of mesh too low on the posterior vagina may be associated with increased mesh exposure and pain secondary to mesh stiffness. No randomized trials exist comparing prolapse outcomes using new, ultra-light polypropylene mesh with and without posterior colpoperineorrhaphy. The investigators hypothesize that there will be no difference in prolapse outcomes after sacrocolpopexy using Restorelle mesh with and without posterior colpoperineorrhaphy. However, patients with a posterior colpoperineorrhaphy will be more likely to report pain with defecation and dyspareunia. This will be the first multicenter randomized trial comparing outcomes of sacrocolpopexy with and without posterior colpoperineorrhaphy.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
200 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
REDUCE Trial - Reducing Prolapse Recurrence by Reducing the Genital Hiatus
Actual Study Start Date :
Nov 23, 2021
Anticipated Primary Completion Date :
Jan 1, 2024
Anticipated Study Completion Date :
Jul 30, 2024

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Sacralcolpopexy with posterior colpoperineorrhaphy

Procedure: Posterior colpoperineorrhaphy
Patients having a sacralcolpopexy will be randomized to ultra lightweight mesh (Coloplast Restorelle) with posterior colpoperineorrhaphy or the same procedure without the posterior colpoperineorrhaphy

No Intervention: Sacralcolpopexy without posterior colpoperineorrhaphy

Outcome Measures

Primary Outcome Measures

  1. Pelvic Organ Prolapse Quantification (POP-Q) System [1 Year]

    The POP-Q System will be used to compare the rate of prolapse recurrence at 1 year between women undergoing a sacrocolpopexy with Restorelle mesh with and without a concomitant posterior colpoperineorrhaphy.

Secondary Outcome Measures

  1. Defecatory Dysfunction [1 Year]

    To compare the rates of defecatory dysfunction using the Bristol Stool Scale (stool types measured from type 1-type 7) and the Colorectal-Anal Distress Inventory 8 (measured from 0-100 points).

  2. Dyspareunia [1 Year]

    To compare the rates of dyspareunia between groups using the Female Sexual Function Index (measured from 2-36 points)

  3. Surgical and Perioperative Events: Blood Loss [2 Weeks]

    To compare the estimated blood loss (in milliliters) between groups.

  4. Surgical and Perioperative Events: Operative Time [Day of surgery]

    To compare the operative time (in minutes as listed on the surgical case tracking) between groups.

  5. Surgical and Perioperative Events: Postoperative Pain [2 Weeks]

    To compare postoperative pain scores using a visual analog scale (0-100 points) between groups.

  6. Surgical and Perioperative Events: Pain Medication Use [2 Weeks]

    To compare narcotic pain medication use (in morphine equivalents consumed and reported by patients) between groups.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Women over the age of 18

  • English or Spanish speaking

  • Symptomatic prolapse (stage II or greater) undergoing minimally-invasive sacrocolpopexy with Restorelle ultra lightweight mesh

  • Preoperative genital hiatus with valsalva/strain greater than or equal to 4cm

Exclusion Criteria:
  • Patient has had prior prolapse surgery

  • Patient has inflammatory bowel disease (Crohn's, Ulcerative Colitis)

  • Baseline dyspareunia (patient reports that they have pain with vaginal intercourse when asked as a yes/no)

  • Patients with a score of 7 or greater in any one muscle on the Meister Pelvic Floor Exam

  • Patient planning a concomitant Burch procedure

  • Pregnant

Contacts and Locations

Locations

Site City State Country Postal Code
1 Northwestern University Chicago Illinois United States 60611

Sponsors and Collaborators

  • Northwestern University
  • The Institute of Pelvic Medicine & Reconstructive Surgery, Allentown, Pennsylvania
  • University of Kansas

Investigators

  • Principal Investigator: Julia Geynisman-Tan, M.D, Northwestern University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Julia Geynisman-Tan, Director of Research; Assistant Professor, Northwestern University
ClinicalTrials.gov Identifier:
NCT04880239
Other Study ID Numbers:
  • STU00214588
First Posted:
May 10, 2021
Last Update Posted:
Dec 29, 2021
Last Verified:
Dec 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Dec 29, 2021